Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society.
Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes / Catafau A.M.; Tolosa E.; Laloux P.; Vander Borght T.; Van Zandijcke M.; De Geeter F.; Destee A.; Steinling M.; Lacomblez L.; Habert M.-O.; Weiller C.; Clausen M.; Bogdahn U.; Haass A.; Kirsch C.-M.; Antonini A.; Benti R.; Sorbi S.; Pupi A.; Cunha L.; de Lima J.P. Joao Pedroso; Vallderiola F.; Lomena F.; Kulisevsky J.; Catafau A.M.; Weeks R.; Buxton-Thomas M.; Gibb W.R.G.; Kemp P.M.; Asenbaum S.; Dudczak R.. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - STAMPA. - 19:(2004), pp. 1175-1182. [10.1002/mds.20112]
Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes
Sorbi S.;Pupi A.;
2004
Abstract
Imaging with 123I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS] from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of 123I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
